APA

Uppuluri P., Lin L., Alqarihi A., Luo G., Youssef E. G., Alkhazraji S., Yount N. Y., Ibrahim B. A., Bolaris M. A., Edwards J. E., Swidergall M., Filler S. G., Yeaman M. R. & Ibrahim A. S. (20180705). The Hyr1 protein from the fungus Candida albicans is a cross kingdom immunotherapeutic target for Acinetobacter bacterial infection. : PLoS pathogens.

Chicago

Uppuluri Priya, Lin Lin, Alqarihi Abdullah, Luo Guanpingsheng, Youssef Eman G, Alkhazraji Sondus, Yount Nannette Y, Ibrahim Belal A, Bolaris Michael Anthony, Edwards John E, Swidergall Marc, Filler Scott G, Yeaman Michael R and Ibrahim Ashraf S. 20180705. The Hyr1 protein from the fungus Candida albicans is a cross kingdom immunotherapeutic target for Acinetobacter bacterial infection. : PLoS pathogens.

Harvard

Uppuluri P., Lin L., Alqarihi A., Luo G., Youssef E. G., Alkhazraji S., Yount N. Y., Ibrahim B. A., Bolaris M. A., Edwards J. E., Swidergall M., Filler S. G., Yeaman M. R. and Ibrahim A. S. (20180705). The Hyr1 protein from the fungus Candida albicans is a cross kingdom immunotherapeutic target for Acinetobacter bacterial infection. : PLoS pathogens.

MLA

Uppuluri Priya, Lin Lin, Alqarihi Abdullah, Luo Guanpingsheng, Youssef Eman G, Alkhazraji Sondus, Yount Nannette Y, Ibrahim Belal A, Bolaris Michael Anthony, Edwards John E, Swidergall Marc, Filler Scott G, Yeaman Michael R and Ibrahim Ashraf S. The Hyr1 protein from the fungus Candida albicans is a cross kingdom immunotherapeutic target for Acinetobacter bacterial infection. : PLoS pathogens. 20180705.